Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Table 1 Sample characteristics

	Non-carriers	ADAD mutation carriers		Sporadic Alzheimer’s disease		MCI-
	Non-carriers	Presymptomatic	Symptomatic	MCI+	AD	MCI-
n at baseline	14 ¹	6 ²	4 ³	11	4	4
Estimated years from symptom onset at baseline PET	2 [-4 : 9]	-7 [-11 : -4]	1, 3, 6, 8	-	-	-
Age at baseline PET	56 [45 : 63]	44 [42 : 47]	55, 57, 58, 64	60 [57: 67]	56, 67, 67, 70	54, 60, 61, 72
Plasma GFAP concentration at baseline PET	138 [65 : 161]	116 [84 : 141]	71, 285 ⁴	118 [100 : 140]	117, 137, 196, 275	76, 78, 95, 144
Follow-up interval for PET (years)	3.1 [2.6 : 3.7]	2.5 [2.4 : 2.9]	2.8	-	-	-
n with follow-up PET (number of total follow-up investigations)	4 (4)	5 (5)	1 (1)	-	-	-
Follow-up interval for plasma GFAP (years)	14.8 [5.3 : 15.7]	16.3 [6.9 : 21.0]	15.5, 18.2	-	-	-
n with follow-up plasma sampling (number of total follow-up investigations)	13 (22)	6 (22)	2 (9)	-	-	-

The data are presented as median [interquartile range], unless otherwise indicated. In groups with n < 5, the individual values for each variable are presented
¹ C-PIB data were not available for one participant (n = 1)
² One participant was carrier of the APParc mutation (n = 1)
³ Two participants were carriers of the APParc mutation (n = 2)
⁴ Plasma GFAP measures were not available for two participants (n = 2)
NC: non-carriers; pMC: presymptomatic mutation carriers; sMC: symptomatic mutation carriers; MCI-: MCI with a negative amyloid-β PET scan; MCI+: MCI with a positive amyloid-β PET scan; AD: Alzheimer’s disease dementia

ISSN: 1750-1326